Novo Nordisk launches type 2 diabetes awareness campaign

Novo Nordisk UK has launched a new awareness campaign aimed at people living with type 2 diabetes and their families.

This follows repeated warnings from leading healthcare professionals and charities that more must be done to reduce cardiovascular disease, including heart attacks and strokes, in those living with type 2 diabetes.

The ‘don’t miss a beat in type 2 diabetes’ campaign comprises an informative website, video animation, online Q&A, and is being fronted by Christopher Biggins, who himself lives with type 2 diabetes.

Cardiovascular disease is largely preventable, yet the impact is severe. The cost to the NHS is also severe, with over £7 billion spent each year managing complications caused by type 2 diabetes. The largest cost for complications is cardiovascular disease.

New data from the International Diabetes Federation reveals that two in three people living with type 2 diabetes have cardiovascular disease risk factors such as high blood pressure, uncontrolled blood glucose levels and high cholesterol.

Lifestyle and medication can be used to lower the risk of a person experiencing cardiovascular disease, and people living with type 2 diabetes are encouraged to meet targets for blood glucose, cholesterol and blood pressure, working with their healthcare professional in order to achieve this. Unfortunately, only 40% of people living with type 2 diabetes meet all three targets.

Despite the significant impact, two in three people living with type 2 diabetes have admitted that they need more information about cardiovascular disease and the risks.

Dr Naresh Kanumilli is a South Manchester GP with a special interest in diabetes and cardiology, and Clinical Champion for patient organisation Diabetes UK. He’s backing the campaign and encouraging people living with type 2 diabetes to take steps to reduce their risk.

He said: “The effects of cardiovascular disease on the person, their family, and society, cannot be underestimated. For too long, the focus for managing type 2 diabetes has been on managing blood sugars and while that remains an important aspect, cardiovascular risk can no longer be overlooked.

“We need a holistic approach to managing type 2 diabetes that places prevention of cardiovascular disease at the heart of our efforts. There are many simple steps that can be taken to lower a person’s risk, which will see them reap the rewards in terms of their health both now and in the future.”

Dr Avideh Nazeri, Director of Clinical, Medical and Regulatory for Novo Nordisk UK, said: “It is clear that cardiovascular disease is a serious and concerning problem for people living with type 2 diabetes in the UK, and that many do not have the necessary information to better understand their risk.

“The good news is that cardiovascular disease is largely preventable, and we must help people living with type 2 diabetes by giving them the right information at the right time so that they know what they can do to lower their risk.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

FDA approves Roche’s Phesgo for HER2-positive breast cancer

The FDA has approved Phesgo, the fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous injection in combination with intravenous...

Carmine Therapeutics & Takeda to develop novel on-viral gene therapies

Carmine Therapeutics has signed a research collaboration agreement with Takeda to discover, develop and commercialise transformative non-viral gene therapies for two rare disease targets...

Catalent to fill-finish manufacture Moderna’s COVID-19 vaccine canidate

Moderna and Catalent have entered into a collaboration for large-scale, commercial fill-finish manufacturing of the former’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at the latter’s...

Enrolment opens for 4D Pharma’s phase II study of live biotherapeutic in COVID-19

4D Pharma, the listed Leeds-based pharma company developing Live Biotherapeutics, has announced that its Phase II clinical trial of oral immunomodulator MRx-4DP0004 for patients...

Pharma industry invests £381m in UK R&D activities

The pharmaceutical industry has invested £381.2 million on R&D activities in the UK during 2019, up from £377.3 million in 2018, according to new...

Related news

CDMOs team up to simplify processes, optimise time-to-market

CDMOs Vetter and Rentschler Biopharma are collaborating to enhance their services and offer complementary skills and experience along the biopharmaceutical value chain. With drug development...

FDA approves Roche’s Phesgo for HER2-positive breast cancer

The FDA has approved Phesgo, the fixed-dose combination of Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous injection in combination with intravenous...

Carmine Therapeutics & Takeda to develop novel on-viral gene therapies

Carmine Therapeutics has signed a research collaboration agreement with Takeda to discover, develop and commercialise transformative non-viral gene therapies for two rare disease targets...

Catalent to fill-finish manufacture Moderna’s COVID-19 vaccine canidate

Moderna and Catalent have entered into a collaboration for large-scale, commercial fill-finish manufacturing of the former’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at the latter’s...